Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

This study has been completed.

First Received: March 26, 2004 Last Updated: June 27, 2008 History of Changes

Sponsor:	Bristol-Myers Squibb
Collaborator:	Otsuka America Pharmaceutical
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00080314

Purpose

The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.

Condition	Intervention	Phase
Bipolar Disorder	Drug: Aripiprazole Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder Depression

Drug Information available for: Aripiprazole

U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

Change on a depression rating scale at endpoint

Secondary Outcome Measures:

Response rate and Clinical Global Impression scale at endpoint

Estimated Enrollment:	400
Study Start Date:	January 2004

Arms	Assigned Interventions
A1: Active Comparator	Drug: Aripiprazole Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
A2: Placebo Comparator	Drug: Placebo Tablets, Oral, 0 mg, Once daily, 8 weeks.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

ages 18-65
Men and women, who have experienced a prior manic episode that required hospitalization, and now meet criteria for a major depressive episode.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00080314

Show 29 Study Locations

Sponsors and Collaborators

Bristol-Myers Squibb

Otsuka America Pharmaceutical

Investigators

Study Director:

Bristol-Myers Squibb

More Information

Additional Information:

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CN138-096
Study First Received:	March 26, 2004
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00080314 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:

Bipolar 1 Disorder, depressed

Additional relevant MeSH terms:

Disease
Tranquilizing Agents
Bipolar Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antipsychotic Agents
Pharmacologic Actions

Affective Disorders, Psychotic
Pathologic Processes
Mental Disorders
Therapeutic Uses
Mood Disorders
Aripiprazole
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 09, 2009